Please use this identifier to cite or link to this item: https://doi.org/10.1097/00007890-199107000-00025
Title: The immunosuppressive antagonism of low doses of FK506 and cyclosporine
Authors: Vathsala, A 
Goto, S
Yoshimura, N
Stepkowski, S
Chou, TC
Kahan, BD
Keywords: Animals
Anti-Bacterial Agents
Cyclosporins
DNA Replication
Dose-Response Relationship, Drug
Drug Antagonism
Graft Survival
Heart Transplantation
Humans
Immunosuppressive Agents
Interleukin-2
Lymphocyte Culture Test, Mixed
Lymphocytes
Male
Phytohemagglutinins
Rats
Rats, Inbred WF
Tacrolimus
Issue Date: 1-Jan-1991
Publisher: Ovid Technologies (Wolters Kluwer Health)
Citation: Vathsala, A, Goto, S, Yoshimura, N, Stepkowski, S, Chou, TC, Kahan, BD (1991-01-01). The immunosuppressive antagonism of low doses of FK506 and cyclosporine. Transplantation 52 (1) : 121-128. ScholarBank@NUS Repository. https://doi.org/10.1097/00007890-199107000-00025
Abstract: Clinical immunosuppression with potentially toxic agents may be optimized by combining drugs that act synergistically at low doses. The studies presented herein attempted to apply this strategy to the macrolide FK506 and the endecapeptide cyclosporine, which similarly inhibit T cell responses but display distinctive arrays of toxic side effects. The interaction between these agents was subjected to rigorous pharmacologic analysis using the median effect and combination index equations to determine synergistic, antagonistic, or additive drug interactions. FK506 and CsA showed pharmacologic antagonism in inhibiting in vitro proliferation upon phytohemagglutinin, anti-CD3 antibody, and mixed lymphocyte reaction (MLR) stimulation, and interleukin 2 generation by activated normal human peripheral blood lymphocytes. The antagonistic relationship was confirmed in vivo using low doses of FK506 in combination with CsA to treat Wistar-Furth recipients of heterotopic Buffalo rat cardiac allografts, a major plus minor histocompatibility barrier. This antagonistic relation suggests that FK506/CsA combination therapy does not permit dose reduction of the individual drugs to mitigate toxic complications. © 1991 by Williams & Wilkins.
Source Title: Transplantation
URI: https://scholarbank.nus.edu.sg/handle/10635/229617
ISSN: 00411337
15346080
DOI: 10.1097/00007890-199107000-00025
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Transplantation - Antagonism of FK506 and Cyclosporine.pdf712.01 kBAdobe PDF

CLOSED

Published

SCOPUSTM   
Citations

30
checked on Sep 23, 2022

Page view(s)

22
checked on Sep 22, 2022

Download(s)

4
checked on Sep 22, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.